
    
      Group 1 used metformin (1000 mg bid) and gliclazide (60 mg qd); Group 2 used the same amounts
      of metformin and gliclazide, with the addition of vildagliptin (50 mg bid). The patients were
      prospectively assigned to each of these two groups for the purpose of this study. Using
      Doppler ultrasound, all cases were measured for portal vein flow velocity, portal vein flow
      and portal vein diameter. Degree of hepatosteatosis was also recorded.
    
  